Aura Biosciences (AURA) Current Assets (2020 - 2026)
Aura Biosciences' (AURA) quarterly Current Assets came in at $118.5 million in Q1 2026, down 11.9% YoY from $134.5 million in Q1 2025, and down 20.86% on a QoQ basis from $149.7 million in Q4 2025.
Aura Biosciences (AURA) Current Assets (2020 - 2026) Analysis & Trends
Aura Biosciences (AURA) has 7 years of Current Assets data on file, last reported at $118.5 million in Q1 2026.
- Quarterly Current Assets fell 11.9% year-over-year to $118.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $118.5 million (down 11.9% YoY) and the FY2025 annual result came in at $149.7 million, down 6.78% from the prior year.
- Current Assets slipped to $118.5 million in Q1 2026, from $149.7 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $231.8 million in Q4 2023 to a low of $115.9 million in Q3 2022.
- A 5-year average of $165.9 million and a median of $166.2 million in 2023 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2022 — Current Assets soared 38.88% — and 2025, when it plunged 36.62%.
- Tracing AURA's Current Assets over 5 years: stood at $196.7 million in 2022, then climbed by 17.84% to $231.8 million in 2023, then tumbled by 30.7% to $160.6 million in 2024, then declined by 6.78% to $149.7 million in 2025, then retreated by 20.86% to $118.5 million in 2026.
- The last three Current Assets figures came in at $118.5 million (Q1 2026), $149.7 million (Q4 2025), and $170.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Aura Biosciences | 797.49 Mn | 729.65 Mn | - | 329.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 329.03 Mn |
| Mar 31, 2026 | 118.50 Mn |
| Dec 31, 2025 | 149.74 Mn |
| Sep 30, 2025 | 170.12 Mn |
| Jun 30, 2025 | 183.96 Mn |
| Mar 31, 2025 | 134.52 Mn |
| Dec 31, 2024 | 160.62 Mn |
| Sep 30, 2024 | 183.48 Mn |
| Jun 30, 2024 | 195.60 Mn |
| Mar 31, 2024 | 212.25 Mn |
| Dec 31, 2023 | 231.79 Mn |
| Sep 30, 2023 | 153.89 Mn |
| Jun 30, 2023 | 166.21 Mn |
| Mar 31, 2023 | 179.12 Mn |
| Dec 31, 2022 | 196.70 Mn |
| Sep 30, 2022 | 115.91 Mn |
| Jun 30, 2022 | 127.67 Mn |
| Mar 31, 2022 | 139.58 Mn |
| Dec 31, 2021 | 153.70 Mn |
| Sep 30, 2021 | 83.46 Mn |